Zhang W, Wang P, Zhao Y
Second Teaching Hospital, Bethune University of Medical Sciences, Changchun 130041.
Zhonghua Yi Xue Za Zhi. 1999 Mar;79(3):194-6.
To study the clinical significance for measureing serum immunosuppresive acidic protein (IAP) levels to diagnoze and follow up survey patients with the gynecological tumor.
Serum IAP levels were determined by IAP-single radial immunodiffusion test in 235 patients with gynecological tumor, 38 patients had benign ovary tumor, 41 were malignant ovary tumor, 66 hysteromyoma, 34 cervical carcinoma, 16 endometrial carcinoma, 27 received chemotherapy, and 13 had tumor recurrence. The control group consisted of 50 health women.
The serum IAP level was (889 +/- 208) mg/L in malignant ovary tumor, and higher than that of the health women and benign ovary tumor, (P < 0.01). In patients with cervical carcinoma and endometrial carcinoma, the IAP level was (741 +/- 213) and (763 +/- 209) mg/L respectively, and higher than that of the health women and benign ovary tumor (P < 0.01). After chemotherapy, the serum IAP level of malignant ovary tumor was decreased. In patients with recurrence of ovary tumor, the IAP levels was increased to compare with the health women (P < 0.01), the incidence of the abnormal value was 100%.
Detecting IAP level of the gynecological tumor may be an auxiliary index for monitoring gynecological tumor and identifying whether it is benign or malignant.
探讨检测血清免疫抑制酸性蛋白（IAP）水平对妇科肿瘤患者诊断及随访的临床意义。
采用IAP单向免疫扩散试验检测235例妇科肿瘤患者血清IAP水平，其中卵巢良性肿瘤38例，卵巢恶性肿瘤41例，子宫肌瘤66例，宫颈癌34例，子宫内膜癌16例，27例接受化疗，13例肿瘤复发。对照组为50名健康女性。
卵巢恶性肿瘤患者血清IAP水平为（889±208）mg/L，高于健康女性及卵巢良性肿瘤患者（P<0.01）。宫颈癌和子宫内膜癌患者血清IAP水平分别为（741±213）和（763±209）mg/L，高于健康女性及卵巢良性肿瘤患者（P<0.01）。化疗后，卵巢恶性肿瘤患者血清IAP水平下降。卵巢肿瘤复发患者血清IAP水平较健康女性升高（P<0.01），异常值发生率为100%。
检测妇科肿瘤患者IAP水平可能是监测妇科肿瘤及鉴别其良恶性的一项辅助指标。
